Naringenin triacetate

CAS No. 3682-04-0

Naringenin triacetate( —— )

Catalog No. M30951 CAS No. 3682-04-0

Naringenin triacetate exhibits a better binding affinity with multiple crystal structures of first bromodomain BRD4 (BRD4 BD1) when compared with the known inhibitors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 102 In Stock
10MG 163 In Stock
25MG 274 In Stock
50MG 402 In Stock
100MG 582 In Stock
200MG 821 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Naringenin triacetate
  • Note
    Research use only, not for human use.
  • Brief Description
    Naringenin triacetate exhibits a better binding affinity with multiple crystal structures of first bromodomain BRD4 (BRD4 BD1) when compared with the known inhibitors.
  • Description
    Naringenin triacetate exhibits a better binding affinity with multiple crystal structures of first bromodomain BRD4 (BRD4 BD1) when compared with the known inhibitors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    3682-04-0
  • Formula Weight
    398.4
  • Molecular Formula
    C21H18O8
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (251.03 mM)
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Azadirachtin B

    Azadirachtin B is an limonoid isolated from seed kernels of Azadirachta indica and it is active against the Epstein-Barr virus early antigen (EBV-EA).

  • Mast Cell Degranulat...

    Peptide from giant hornet Vespa orientalis that has biological effects similar to mast cell degranulating peptide from bee venom.

  • 3-Methyladipic acid

    3-Methyladipic acid is a metabolite of the catabolism of phytanic acid. Patients with adult Refsums disease (ARD) are unable to detoxify phytanic acid by alpha-oxidation and so the w-oxidation pathway is the only metabolic pathway available for phytanic acid degradation.